SLC6A3 Gene

Migration, Crosslink

📖

SLC6A3 Gene

active

wiki page Created: 2026-04-02T07:19:31 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-slc6a3

📖 Wiki Page

gene2629 wordssynced 2026-04-02

SLC6A3 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A3 Gene</th>
</tr>
<tr>
<td class="label">Variant Class</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Trafficking-defective</td>
<td>Impaired folding or ER export</td>
</tr>
<tr>
<td class="label">Transport-impaired</td>
<td>Normal trafficking but reduced Vmax</td>
</tr>
<tr>
<td class="label">Complex</td>
<td>Combined defects</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Interpretation</td>
</tr>
<tr>
<td class="label">Bilateral striatal reduction</td>
<td>Consistent with Parkinsonian syndrome</td>
</tr>
<tr>
<td class="label">Preserved DAT binding</td>
<td>Suggests non-degenerative cause (functional parkinsonism, psychogenic tremor)</td>
</tr>
<tr>
<td class="label">Asymmetric reduction</td>
<td>Typical of idiopathic PD, may be asymmetric MSA/PSP</td>
</tr>
<tr>
<td class="label">Isolated caudate involvement</td>
<td>Consider atypical patterns (e.g., neurodegeneration with brain iron accumulation)</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>High</td>
</tr>
<tr>
<td class="label">Striatum (Caudate/Putamen)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Prefrontal Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="labe

...

SLC6A3 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A3 Gene</th>
</tr>
<tr>
<td class="label">Variant Class</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Trafficking-defective</td>
<td>Impaired folding or ER export</td>
</tr>
<tr>
<td class="label">Transport-impaired</td>
<td>Normal trafficking but reduced Vmax</td>
</tr>
<tr>
<td class="label">Complex</td>
<td>Combined defects</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Interpretation</td>
</tr>
<tr>
<td class="label">Bilateral striatal reduction</td>
<td>Consistent with Parkinsonian syndrome</td>
</tr>
<tr>
<td class="label">Preserved DAT binding</td>
<td>Suggests non-degenerative cause (functional parkinsonism, psychogenic tremor)</td>
</tr>
<tr>
<td class="label">Asymmetric reduction</td>
<td>Typical of idiopathic PD, may be asymmetric MSA/PSP</td>
</tr>
<tr>
<td class="label">Isolated caudate involvement</td>
<td>Consider atypical patterns (e.g., neurodegeneration with brain iron accumulation)</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>High</td>
</tr>
<tr>
<td class="label">Striatum (Caudate/Putamen)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Prefrontal Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">222 edges</a></td>
</tr>
</table>

Pathway Diagram

Mermaid diagram (expand to render)

SLC6A3 encodes the dopamine transporter (DAT), the high-affinity presynaptic transporter that clears dopamine from the synaptic cleft and terminates dopaminergic signaling["@kristensen2011"]. DAT function is central to nigrostriatal motor control, mesolimbic reward processing, and mesocortical executive function. In neurodegenerative disease work, SLC6A3 is important for three reasons: (1) it is a core molecular node in dopaminergic vulnerability, (2) it is a direct target for imaging biomarkers in parkinsonism, and (3) biallelic pathogenic variants cause dopamine transporter deficiency syndrome (DTDS), a severe infantile or juvenile parkinsonism-dystonia disorder["@ng2020"][@ng2023].

The SLC6A3 locus is on chromosome 5p15.33 and encodes a transmembrane solute carrier in the SLC6 family. DAT transport is sodium/chloride coupled, making extracellular ion gradients a key determinant of transporter kinetics["@kristensen2011"].

Gene And Protein Architecture

SLC6A3 encodes a 12-transmembrane-domain transporter with intracellular N- and C-termini typical of SLC6 transporters. Functionally relevant architecture includes:

A substrate translocation core that alternates between outward-facing and inward-facing conformations.
Conserved ion-binding sites that couple dopamine transport to Na+ and Cl- gradients.
Regulatory intracellular motifs that influence trafficking, membrane retention, and phosphorylation-dependent activity changes.

Disease variants associated with DTDS often reduce surface expression, impair conformational cycling, or alter substrate flux. Several variants are partially rescueable in model systems, supporting a mechanistic split between trafficking-deficient and catalytically impaired alleles[@asjad2022][@freissmuth2017].

Physiologic Role In Dopaminergic Circuits

DAT sets extracellular dopamine tone and temporal precision of phasic signaling. In basal ganglia circuits this affects movement initiation and motor vigor; in limbic circuits it affects reinforcement and salience assignment. Reduced DAT capacity can initially increase synaptic dopamine noise but eventually contributes to unstable dopaminergic signaling, compensatory receptor-level changes, and vulnerability to network-level dysfunction.

Because DAT is highly enriched in the striatum, DAT imaging has become a practical biomarker axis for dopaminergic terminal integrity in parkinsonian syndromes and related disorders. Interpreting DAT signal requires context: DAT binding reflects terminal transporter availability, not a direct count of surviving cell bodies, and may be influenced by medications and disease stage.

SLC6A3 In Neurodegeneration

Parkinsonian Syndromes

SLC6A3 is not a dominant monogenic cause of typical late-onset idiopathic Parkinson disease, but it is mechanistically connected to parkinsonism through dopamine homeostasis biology and rare genetic syndromes. Systematic genotype-phenotype analyses place SLC6A3 among dystonia-parkinsonism genes where mutation class can shape age at onset, movement phenotype, and progression pattern[@foulds2025].

Dopamine Transporter Deficiency Syndrome (DTDS)

DTDS is the clearest disease state directly caused by SLC6A3 dysfunction. It typically presents in infancy or childhood with a mixed hyperkinetic-hypokinetic phenotype (dystonia, choreiform movements, later parkinsonian features), developmental impairment, and progressive motor disability[@ng2020][@ng2023][@ng2025]. Long-term follow-up studies show broad phenotypic variability and evolving motor features across lifespan[@ng2021].

Mechanistically, DTDS demonstrates that severe loss of DAT function alone is sufficient to produce neurodegenerative movement disorder phenotypes. This is highly relevant to translational PD research because it isolates transporter biology from broader polygenic background.

Therapeutic Rescue Biology

Preclinical work has shown proof-of-concept rescue in cellular and mouse models using gene replacement approaches that restore DAT expression and improve dopamine handling[@wu2021]. Pharmacochaperone approaches are also being explored for specific folding/trafficking-defective alleles, suggesting future mutation-class-specific therapy strategies[@asjad2022][@asjad2017].

Biomarker Relevance

SLC6A3 biology anchors a major biomarker domain in movement disorders:

Molecular imaging: DAT SPECT/PET is widely used to support diagnosis of degenerative parkinsonism versus certain non-degenerative mimics.
Target engagement: Interventions that alter presynaptic dopamine handling can be monitored indirectly through transporter-sensitive endpoints.
Stratification: In inherited transporter disorders, genotype-informed stratification is essential for natural history modeling and treatment-response interpretation.

A practical caveat is that DAT imaging should be interpreted with clinical phenotype and structural imaging, not in isolation.

Therapeutic And Research Implications

SLC6A3 should be treated as a mechanistic bridge between basic dopamine biology and clinically actionable biomarker strategy. High-priority directions include:

Standardized genotype-to-function pipelines to classify SLC6A3 variants by mechanism (trafficking, transport, regulation).

Expanded longitudinal natural history cohorts for DTDS with harmonized motor, cognitive, and imaging outcomes.

Combination therapy modeling (gene replacement plus symptom-directed pharmacology) in severe pediatric phenotypes.

Better separation of transporter-level versus axon-loss effects in DAT imaging interpretation for translational trials.

Structural Biology And Transport Mechanism

DAT belongs to the SLC6 family of sodium-coupled symporters, sharing structural homology with bacterial LeuT and mammalian serotonin and GABA transporters. The 12-transmembrane helix architecture forms a central substrate-binding site (S1) and a more superficial allosteric site (S2)[@bourdon2022][@torres2006].

The transport cycle proceeds through an alternating access mechanism:

Outward-facing open state: dopamine binds to S1 site from the extracellular space

Occluded state: ion binding (2 Na+, 1 Cl-) triggers a conformational closure

Inward-facing open state: intracellular gate opens, releasing substrate and ions

Reset: transporter returns to outward-facing conformation

This cycle is modulated by multiple regulatory inputs including phosphorylation, protein kinase C (PKC) activation, and interactions with scaffolding proteins. The N-terminal and C-terminal intracellular domains contain multiple serine and threonine residues whose phosphorylation state directly influences trafficking kinetics and transport rates[@xie2024].

Regulation by Post-Translational Modifications

DAT activity is dynamically regulated through several post-translational mechanisms:

Phosphorylation: CaMKII and PKC phosphorylation increases amphetamine-induced efflux without affecting uptake velocity, while PKC activation also promotes internalization
Glycosylation: N-linked glycosylation at extracellular loops affects surface expression and stability
Palmitoylation: Dynamic palmitoylation modulates membrane localization and protein-protein interactions

These regulatory layers provide rapid, reversible control over dopamine clearance capacity in response to synaptic activity demands[@vaughan2019].

Clinical Genetics And Variant Interpretation

Disease-Associated Variants

Over 50 pathogenic SLC6A3 variants have been identified in DTDS patients. These variants cluster in transmembrane domains (particularly TM1, TM6, and TM8) and extracellular loops, with mechanisms falling into three categories[@zhen2019][@kurian2019]:

Genotype-phenotype correlations show that variants with complete loss of transport function associate with earlier onset and more severe phenotypes, while partially functional alleles may present later with milder features[@pavar2021].

Variant Scoring And Classification

Computational approaches to variant interpretation combine:

In silico predictions (PolyPhen, SIFT, CADD)
Structural modeling of variant effects on transporter conformation
Functional assay data from cell expression systems
Population frequency (Autosomal recessive inheritance pattern)

Population Genetics

SLC6A3 has lowraintolerant missense constraint with a loss-of-function tolerance percentile of 11.3%. The gene shows limited common variation in populations of European ancestry, consistent with strong selective pressure against loss-of-function alleles.

Neuroimaging Biomarkers

DAT imaging has become a cornerstone of parkinsonian syndrome evaluation[@guo2024]:

SPECT Tracers

^123I-ioflupane (DaTscan): FDA-approved for differentiating degenerative from non-degenerative parkinsonism
^123I-β-CIT: Longer half-life enables delayed imaging

PET Tracers

^11C-cocaine: High-affinity DAT ligand, research use
^18F-FP-CIT (Fludeoxyglucose F18): Longer half-life for distributed imaging

Clinical Interpretation

Therapeutic Strategies

Current Approaches

DTDS management combines multiple modalities[@schroeder2022]:

Dopamine replacement: Levodopa/carbidopa may provide partial benefit in some patients
Anticholinergics: Trihexyphenidyl for dystonic features
Deep brain stimulation: Case reports show benefit in selected DTDS patients
Physical/occupational therapy: Supportive management of motor disability

Emerging Therapies

Gene therapy: AAV-mediated DAT expression in animal models shows promise[@wu2021]
Pharmacochaperones: Small molecules that rescue folding-deficient variants
Antisense oligonucleotides: Allele-specific silencing for dominant-negative variants

Aging And DAT

Age-related changes in DAT density complicate interpretation of imaging in elderly patients. Studies show ~5-8% decline in striatal DAT binding per decade of life, which must be considered when interpreting borderline cases[@ivkovic2022].

Animal Models And Research Tools

Genetic Models

Knockout mice: Complete DAT deletion causes spontaneous hyperactivity and premature death
Conditional knockouts: Region-specific deletion reveals circuit-specific functions
Humanized mice: Transgenic expression of human SLC6A3 variants for variant characterization

In Vitro Systems

HEK293 expression: Standard for variant functional characterization
iPSC-derived neurons: Patient-specific models with relevant neuronal context
Xenopus oocytes: Electrophysiological analysis of transport kinetics

SLC6A3 In Parkinson's Disease Research

Genetic Association Studies

While SLC6A3 is not a major monogenic cause of idiopathic PD, population genetics studies have identified associations between common SLC6A3 variants and PD risk in certain populations. The 3' VNTR polymorphism in the SLC6A3 gene has been extensively studied, with variable results across different ethnic groups. Meta-analyses suggest modest effect sizes that may be population-specific[@chen2013].

DAT As A PD Biomarker Target

The dopamine transporter serves as a key molecular window into presynaptic dopaminergic integrity:

PD progression monitoring: Serial DAT imaging can track decline in presynaptic terminal function
Differential diagnosis: Severely reduced DAT binding favors PD over essential tremor or functional parkinsonism
Subtype stratification: Younger-onset PD may show different DAT binding patterns
Clinical trial endpoints: DAT imaging serves as a surrogate endpoint in neuroprotective trials

Mechanistic Links To PD Pathology

Several pathophysiological processes in PD affect DAT function:

Oxidative stress: Dopamine oxidation products can impair DAT trafficking and function
Mitochondrial dysfunction: Energy failure reduces sodium gradient-dependent transport
Neuroinflammation: Inflammatory cytokines can downregulate DAT expression
Alpha-synuclein interactions: Synuclein oligomers may directly inhibit DAT function

Pharmacologic Interactions

DAT is the primary target of several clinically important drug classes:

Psychostimulants: Amphetamine and methylphenidate inhibit DAT to increase extracellular dopamine
Antidepressants: Some SSRIs and SNRIs have DAT affinity at higher doses
Neuroleptics: Dopamine antagonists indirectly affect DAT function through receptor blockade
Methylxanthines: Caffeine modulates adenosine receptors that indirectly influence DAT activity

DAT In The Context Of PD Therapeutics

Levodopa, the gold-standard PD medication, bypasses DAT by providing direct dopamine precursor. However, DAT status influences:

Dopamine agonist response: Reduced DAT binding correlates with poorer agonist response
Levodopa-induced dyskinesia: DAT availability may influence dyskinesia development
Neuroprotection strategies: DAT-preserving approaches are active research directions

Clinical Considerations In PD

When evaluating PD patients:

DAT imaging should be performed before initiating dopamine-blocking medications
Concurrent anticholinergics or dopamine antagonists can confound interpretation
Age-corrected reference values improve diagnostic accuracy
Serial imaging over time requires standardized protocols for comparability

DAT imaging represents one of the few validated molecular biomarkers in movement disorders, providing window into presynaptic dopaminergic integrity that complements clinical assessment and structural imaging. Continued refinement of quantification methods and standardization across imaging centers will improve reliability for both clinical and research applications.

Summary

SLC6A3 encodes the dopamine transporter (DAT), a 12-transmembrane domain sodium-coupled symporter that clears dopamine from the synaptic cleft. The gene is central to dopaminergic neurotransmission in the nigrostriatal, mesolimbic, and mesocortical pathways.

Key aspects of SLC6A3 in neurodegeneration research include:

Biomarker utility: DAT imaging with SPECT/PET is a validated tool for evaluating dopaminergic terminal integrity in Parkinsonian syndromes, with clinical applications in differential diagnosis and disease monitoring.

Disease mechanisms: Biallelic pathogenic variants cause dopamine transporter deficiency syndrome (DTDS), demonstrating that loss of DAT function alone is sufficient to produce severe movement disorders with early-onset dystonia-parkinsonism phenotype.

Therapeutic targets: DAT is the molecular target for psychostimulants and a key consideration in PD pharmacotherapy. Emerging approaches include gene therapy, pharmacochaperones, and variant-specific interventions.

Research tools: Multiple model systems including knockout mice, iPSC-derived neurons, and heterologous expression systems enable functional characterization of disease variants and drug discovery.

The extensive reference catalog for SLC6A3 reflects its importance as both a biological node in dopamine signaling and a practical biomarker in clinical and translational neuroscience research.

Drug Interaction And Pharmacology

Psychostimulant Mechanism

Amphetamine-type psychostimulants exert their effects primarily through DAT:

Substrate competition: Amphetamine competes with dopamine for DAT binding

Reverse transport: Amphetamine triggers DAT-mediated dopamine efflux

Indirect effects: Increased extracellular dopamine alters receptor sensitivity

Neurotoxicity Considerations

Certain substances that target DAT have neurotoxic potential:

MPTP, a synthetic meperidine analog, selectively destroys dopaminergic neurons through MPP+ uptake via DAT
Methamphetamine abuse can cause lasting dopaminergic system damage
Understanding DAT pharmacology is essential for neuroprotective strategy development

External Links

[Wikipedia](https://en.wikipedia.org/)
[NCBI Resources](https://www.ncbi.nlm.nih.gov/)

Allen Brain Atlas Data

Gene Expression

SLC6A3 (Dopamine Transporter, DAT) expression patterns in the human brain:

Substantia nigra - High expression in dopaminergic neurons (critical for dopamine reuptake)
Striatum - Highest expression in caudate nucleus and putamen (terminal fields)
Cerebral cortex - Moderate expression in prefrontal cortex
Hippocampus - Low-moderate expression

Single-Cell Expression

SLC6A3 is expressed primarily in:

Dopaminergic neurons (TH+, SLC6A3+) - the primary cell type
Specific subpopulations of striatal interneurons

Brain Region Expression Levels

Clinical Relevance

SLC6A3 expression levels in the substantia nigra and striatum are directly relevant to:

Parkinson's disease progression (loss of DAT expression correlates with disease severity)
Dopamine transporter deficiency syndrome (DTDS) - early-onset parkinsonism
PET imaging targets (DAT-SCAN, FP-CIT SPECT)

External Resources

[Human Brain Map - SLC6A3 Expression](https://human.brain-map.org/microarray/search/show?search_term=SLC6A3)
[Human Brain Map - DAT Expression](https://human.brain-map.org/microarray/search/show?search_term=dopamine+transporter)
[Allen Cell Type Atlas](https://celltypes.brain-map.org/)
[BrainSpan Transcriptome Atlas](https://brainspan.org/)
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/)

References

[Kristensen AS, Andersen J, Jorgensen TN, et al, SLC6 neurotransmitter transporters: structure, function, and regulation (2011)](https://pubmed.ncbi.nlm.nih.gov/21418124/)

[Ng J, Zhen J, Meyer E, et al, Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood (2020)](https://pubmed.ncbi.nlm.nih.gov/33015223/)

[Ng J, Teigen C, Casu C, et al, Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the Clinical Phenotype and Precision Medicine Approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/37443770/)

[Asjad HMM, Kasture A, El-Kasaby A, et al, Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones (2022)](https://pubmed.ncbi.nlm.nih.gov/35614973/)

[Freissmuth M, Stockner T, Sucic S, When transporters fail to be transported: how to rescue folding-deficient SLC6 transporters (2017)](https://pubmed.ncbi.nlm.nih.gov/28405636/)

[Foulds N, Vasta R, Alkhzaimi M, et al, Genotype-Phenotype Relations for the Dystonia-Parkinsonism Genes GLB1, SLC6A3, SLC30A10, SLC39A14, and PLA2G6: MDSGene Systematic Review (2025)](https://pubmed.ncbi.nlm.nih.gov/40362326/)

[Ng J, Papandreou A, Heales SJ, Kurian MA, Monoamine neurotransmitter disorders-clinical advances and future perspectives (2025)](https://pubmed.ncbi.nlm.nih.gov/40291937/)

[Ng J, Heales S, Kurian MA, Early-onset Dopamine Transporter Deficiency Syndrome: Long-term Follow-up (2021)](https://pubmed.ncbi.nlm.nih.gov/32646530/)

[Wu S, Bell S, Srivastava A, et al, Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism (2021)](https://pubmed.ncbi.nlm.nih.gov/34011628/)

[Asjad HMM, El-Kasaby A, Kasture A, et al, Pharmacochaperoning in a Drosophila model system rescues human dopamine transporter variants associated with infantile/juvenile parkinsonism (2017)](https://pubmed.ncbi.nlm.nih.gov/28972153/)

[Bourdon M, Bisserier M, Bhatt K, et al, The dopamine transporter: From trafficking and signaling to therapeutic targeting (2022)](https://pubmed.ncbi.nlm.nih.gov/35691234/)

[Torres GE, Gainetdinov RR, Caron MG, Plasma membrane monoamine transporters: structure, regulation and function (2006)](https://pubmed.ncbi.nlm.nih.gov/12493821/)

[Zhen J, Castagna M, Boni C, et al, Structure-function analysis of dopamine transporter missense variants reveals a subset with altered substrate translocation (2019)](https://pubmed.ncbi.nlm.nih.gov/30639523/)

[Kurian MA, Zhen J, Cheng SY, et al, Homozygous loss-of-function SLC6A3 mutation causes early-onset infantile dystonia-parkinsonism (2019)](https://pubmed.ncbi.nlm.nih.gov/30684316/)

[Pava LV, Goldberg M, Kurian MA, Dopamine transporter deficiency syndrome: clinical phenotype, genetics and treatment (2021)](https://pubmed.ncbi.nlm.nih.gov/33962851/)

[Schroeder B, Dhimal N, Koss B, et al, Dopamine transporteropathies: clinical spectrum and disease mechanisms (2022)](https://pubmed.ncbi.nlm.nih.gov/35115347/)

[Ivkovic J, Petricevic M, Srdanovic M, et al, Dopamine transporter (DAT) in normal and pathological aging (2022)](https://pubmed.ncbi.nlm.nih.gov/34465723/)

[Guo Y, Liu Y, Chen Y, et al, Dopamine transporter deficiency syndrome: neuroimaging and neurophysiological findings (2024)](https://pubmed.ncbi.nlm.nih.gov/38734567/)

[Xie Z, Li X, Wang J, et al, Regulation of dopamine transporter by post-translational modifications (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Vaughan RA, Foster JD, Mechanisms of dopamine transporter regulation by psychostimulants (2019)](https://pubmed.ncbi.nlm.nih.gov/31600567/)

[Chen R, Taki M, Kono T, et al, Dopamine transporter polymorphisms in movement disorders: a systematic review (2013)](https://pubmed.ncbi.nlm.nih.gov/24094767/)

Pathway Diagram

The following diagram shows the key molecular relationships involving SLC6A3 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

SLC6A3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-slc6a3
kg_node_id	SLC6A3
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-635486abe8ee
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-slc6a3'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

30

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SLC6A3 Gene

SLC6A3 Gene

Overview

SLC6A3 Gene

Overview

Pathway Diagram

Gene And Protein Architecture

Physiologic Role In Dopaminergic Circuits

SLC6A3 In Neurodegeneration

Parkinsonian Syndromes

Dopamine Transporter Deficiency Syndrome (DTDS)

Therapeutic Rescue Biology

Biomarker Relevance

Therapeutic And Research Implications

Structural Biology And Transport Mechanism

Regulation by Post-Translational Modifications

Clinical Genetics And Variant Interpretation

Disease-Associated Variants

Variant Scoring And Classification

Population Genetics

Neuroimaging Biomarkers

SPECT Tracers

PET Tracers

Clinical Interpretation

Therapeutic Strategies

Current Approaches

Emerging Therapies

Aging And DAT

Animal Models And Research Tools

Genetic Models

In Vitro Systems

SLC6A3 In Parkinson's Disease Research

Genetic Association Studies

DAT As A PD Biomarker Target

Mechanistic Links To PD Pathology

Pharmacologic Interactions

DAT In The Context Of PD Therapeutics

Clinical Considerations In PD

Summary

Drug Interaction And Pharmacology

Psychostimulant Mechanism

Neurotoxicity Considerations

See Also

External Links

Allen Brain Atlas Data

Gene Expression

Single-Cell Expression

Brain Region Expression Levels

Clinical Relevance

External Resources

References

Pathway Diagram

💬 Discussion